Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy

Publisher： Karger

E-ISSN： 1662-6575|8|1|138-141

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.8, Iss.1, 2015-03, pp. : 138-141

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

By  

Oncology, Vol. 80, Iss. 5-6, 2011-07 ,pp. : 301-306

Karger

Access to resources Recommend Favorite

Oxaliplatin-Induced Lhermitte’s Phenomenon as a Manifestation of Severe Generalized Neurotoxicity

By  

Oncology, Vol. 77, Iss. 6, 2009-12 ,pp. : 342-348

Karger

Access to resources Recommend Favorite

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 3, 2015-09 ,pp. : 581-588

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epididymitis following Cytoreductive Surgery with Intraperitoneal Oxaliplatin Chemotherapy: Two Case Reports

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-02 ,pp. : 138-142

Karger

Access to resources Recommend Favorite

Efficacy of Triplet Combination Chemotherapy with Oxaliplatin, Irinotecan and Capecitabine (OCX) in Metastatic Colorectal Cancer in Relation to RAS/RAF Mutation Status: Results of a Retrospective Analysis

By  

Oncology Research and Treatment, Vol. 37, Iss. 11, 2014-10 ,pp. : 646-652

Karger

Access to resources Recommend Favorite